Clinical Trial Update: Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ABBV-142 in adults with idiopathic pulmonary fibrosis to assess adverse events and changes in disease activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• ABBV-142

Snippet

Sponsor: AbbVie | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: RECRUITING